Synthetic gut microbial communities, known as SynComs, have emerged as powerful platforms for investigating how the trillions of microbes living in the human intestine interact with their host in metabolic diseases. A new review published in Discover Endocrinology and Metabolism on 20 December 2025 evaluates how these defined microbial consortia are constructed, what they have revealed about obesity, insulin resistance and hepatic lipid metabolism, and where their limitations still lie. Written by Julieta Gonzalez-Garcia, Ricardo García-Gamboa and colleagues, the review argues that SynComs overcome key weaknesses of traditional microbiome models, such as ecological variability, low reproducibility and limited mechanistic resolution, by enabling precise control over microbial composition.

The gut microbiota is now recognised as a complex, dynamic and integral component of human health, encompassing bacteria, fungi, viruses, archaea and protozoa that interact with one another and with the host. When this community remains in a balanced state, referred to as eubiosis, these interactions support homeostasis and overall well-being. Dysbiosis, characterised by alterations in the composition, diversity or functionality of the gut microbiota, has been increasingly implicated in the pathogenesis of various diseases. The review notes that defining a precise balance remains challenging, because the microbiome is inherently dynamic and influenced by multiple host and environmental factors.

Among its many functions, the gut microbiota influences host metabolic regulation through several pathways. Dysbiotic shifts have been associated with impaired insulin sensitivity, chronic low-grade inflammation and disruptions in lipid metabolism. In particular, reductions in short-chain fatty acid production and increased intestinal permeability can facilitate the translocation of microbial components such as lipopolysaccharide, which in turn activate inflammatory pathways that compromise glucose and lipid homeostasis. Consequently, gut dysbiosis has been associated with metabolic disorders including obesity, type 2 diabetes mellitus, dyslipidemia and non-alcoholic fatty liver disease. Yet unravelling the specific contributions of the microbiota to these conditions remains difficult because of its vast taxonomic diversity, functional redundancy, and sensitivity to diet, genetics, environment and pharmacological interventions. Inter-individual variability further complicates the identification of consistent microbial signatures or causal mechanisms.

SynComs are defined microbial consortia composed of cultured microorganisms, which may originate from diverse ecological niches including soil, plant-associated environments, aquatic systems or animal hosts. In gut microbiome research, however, SynComs have typically consisted of strains isolated from human intestinal biopsies or faecal samples. These systems allow precise dissection of strain-specific effects, inter-microbial interactions and host responses under standardised, reproducible conditions. Most current SynComs focus on bacterial consortia, reflecting the larger body of evidence available for bacterial systems, although interest in fungal and mixed cross-kingdom communities is growing. The authors describe SynComs as providing a unique balance between ecological relevance and mechanistic resolution, increasingly employed to study host metabolism, immune modulation and microbiome-targeted therapies.

SynComs can be constructed using two complementary strategies: top-down and bottom-up approaches. The top-down approach involves transplanting complex, naturally occurring microbial consortia, often derived from human faecal or mucosal samples, into controlled environments such as gnotobiotic animals or bioreactors. This preserves native ecological interactions and structural complexity, enabling the study of whole-community responses to environmental, dietary or immunological perturbations. A hallmark example cited by the review is a 2013 study by Atarashi and colleagues, who used human faecal microbiota to identify clostridial strains capable of inducing colonic regulatory T cells, validating the consortia in gnotobiotic mice. The bottom-up approach, by contrast, entails the deliberate selection, isolation and co-cultivation of individual microbial strains to assemble defined consortia, enabling precise manipulation of community composition and abundance. In 2016, Desai and colleagues created a 14-member SynCom to demonstrate how dietary fibre deprivation enhances mucin degradation, disrupts the colonic mucus barrier and increases host vulnerability to pathogens.

SynComs can also be tailored along a gradient of complexity, ranging from minimal consortia of two or three strains to complex assemblies comprising dozens of microbial species. Minimal SynComs are particularly suited to elucidating specific mechanisms, such as metabolic pathways or immune responses, under highly controlled conditions, and their simplicity makes them valuable platforms for screening interventions such as prebiotics and postbiotics. In 2024, García-Gamboa and colleagues employed a dual-fungal SynCom consisting of Candida albicans and Candida kefyr to evaluate antifungal postbiotic activity in a synthetic gut model simulating obesity, uncovering strain-specific interactions. Complex SynComs, by contrast, aim to capture broader ecological features of the native gut microbiota, including metabolic cross-feeding, competitive interactions and functional redundancy, and are particularly useful for studying ecosystem-level properties such as colonization resistance or community resilience. In 2018, Wrzosek and colleagues developed a human microbiota-associated mouse model incorporating a complex SynCom derived from human donors to investigate metabolic phenotypes associated with obesity. The review stresses that there is no universal standard for the optimal number of strains; the appropriate complexity depends on the biological question, the desired balance between ecological fidelity and mechanistic resolution, and experimental feasibility.

Defined synthetic consortia have enabled researchers to model disease-specific mechanisms, replicate host phenotypes, identify keystone taxa and evaluate microbiome-targeted interventions. One widely used model is the Simplified Human Intestinal Microbiota, or SIHUMI, composed of seven human-derived strains including Anaerostipes caccae, Bacteroides thetaiotaomicron, Bifidobacterium longum and Escherichia coli, designed to colonise gnotobiotic mice and stably ferment dietary substrates. To enhance butyrate production, Clostridium butyricum was later incorporated, producing the extended model known as SIHUMIx. Within this model, Clostridium ramosum was associated with increased adiposity under a high-fat diet, an effect linked to the upregulation of intestinal nutrient transporters such as GLUT2 and CD36, which enhance the absorption of glucose and fatty acids. Prebiotic supplementation has also been explored in these systems: oligofructose supplementation in SIHUMI-colonised mice improved glucose tolerance and reduced body weight, an effect attributed to propionate-mediated inhibition of hepatic lipogenesis, independently of Bifidobacterium longum. Similarly, inulin supplementation within the SIHUMI-based gnotobiotic mouse model led to a significant increase in cecal and systemic propionate levels, accompanied by altered hepatic gene expression and improved plasma fatty acid profiles.

SynCom-based models have also successfully recapitulated key phenotypes of metabolic disease in vivo. In one study, researchers developed a Simplified Intestinal Microbiota composed of ten sequenced human gut strains to analyse the impact of diet on microbial metabolism and host physiology. When introduced into germ-free mice, this SynCom induced hepatic steatosis, increased adipose tissue mass and elevated blood glucose levels, hallmarks of metabolic syndrome, demonstrating the capacity of defined microbial consortia to drive host metabolic outcomes. Minimal SynComs have proven valuable in uncovering functional mechanisms as well. A two-strain SynCom composed of an engineered Bacillus subtilis designed to produce butyrate, together with Bifidobacterium pseudocatenulatum JJ3, was tested both in vitro and in genetically obese ob/ob mice. This model demonstrated that microbial biosynthesis of vitamin B6 contributed to improved metabolic outcomes, including reduced hepatic steatosis and enhanced glucose tolerance, through the modulation of amino acid metabolism. Beyond phenotype modelling, SynComs have helped identify taxa such as Akkermansia muciniphila, shown to be safe in inflammation-prone mouse models, supporting its potential as a next-generation probiotic, alongside butyrate-producing, immunoregulatory taxa such as Faecalibacterium prausnitzii and Roseburia species.

The review also situates SynComs against traditional microbiome models, including large-scale human cohort studies, germ-free and gnotobiotic animals, antibiotic-treated mice and advanced in vitro gastrointestinal simulators. Landmark initiatives such as the Human Microbiome Project and MetaHIT have provided foundational observational data revealing associations between microbiome composition and metabolic disorders. For example, reduced microbial richness, lower abundance of beneficial taxa such as Faecalibacterium prausnitzii, and altered Firmicutes/Bacteroidetes ratios have been reported in individuals with obesity or type 2 diabetes. However, these studies are largely correlative and often confounded by host genetics, diet, medication use and environmental exposures, limiting their capacity to establish causal relationships. Germ-free mice colonised with faecal microbiota from obese or lean human donors can replicate the donor’s metabolic phenotype, providing evidence for a causal role of the microbiota in energy homeostasis, yet such models suffer from donor-dependent variability and poor microbial engraftment. SynComs overcome some of these limitations by allowing complete control over microbial composition, enhancing reproducibility and enabling hypothesis-driven experimental design. Defined consortia such as the Oligo-Mouse-Microbiota, comprising twelve murine-derived strains, have demonstrated stable colonisation, short-chain fatty acid production and immune maturation in gnotobiotic hosts.

Nevertheless, the authors caution that SynComs are not without limitations and should be viewed as complementary tools rather than replacements for traditional models. Their reduced complexity, typically limited to tens of strains, does not capture the full taxonomic and functional diversity of the native gut microbiota, which comprises thousands of bacterial taxa as well as fungi, archaea and bacteriophages. As a result, SynComs may overlook rare but functionally important species and fail to replicate intricate cross-feeding networks. Most SynComs are designed for murine models, which may not fully reflect human biology because of interspecies differences in immune responses, intestinal architecture and nutrient metabolism, and many strains used in murine SynComs fail to colonise or persist in the human gut. Inter-individual variability in the human microbiome, shaped by genetics, age, diet, geography and prior antibiotic exposure, further complicates the development of universal SynComs. Looking forward, the review highlights emerging solutions including high-throughput anaerobic culturing, organ-on-chip platforms, multi-omics integration, computational and artificial intelligence modelling, synthetic biology and personalised SynComs built from patient-derived microbiome profiles. Pilot clinical trials are beginning to test the safety, colonisation dynamics and metabolic efficacy of defined SynComs in human subjects, and the authors conclude that these modular, reproducible and engineerable communities are poised to become integral to microbiome-based precision medicine in metabolic health.

Subject of Research: Synthetic gut microbial communities as controlled experimental models for studying microbiome–host interactions in metabolic diseases

Article Title: Synthetic microbial communities as novel models to study gut microbiome–host interactions in metabolic diseases

Article References: Gonzalez-Garcia, J., Delgado-Villalobos, A., Hernandez-Ruiz, G., Díaz-Torres, O., García-Cayuela, T., Gradilla-Hernández, M. S., González-Avila, M., Gómez-Sandoval, J. R., Rodríguez-Montaño, R., Bayardo-González, R. A., & García-Gamboa, R. (2025). Synthetic microbial communities as novel models to study gut microbiome–host interactions in metabolic diseases. Discover Endocrinology and Metabolism, 1(1), Article 12. https://doi.org/10.1007/s44417-025-00012-1

Image Credits: AI Generated

DOI: 10.1007/s44417-025-00012-1

Keywords: SynComs, gut microbiome, metabolic diseases, obesity, insulin resistance, gnotobiotic mice, short-chain fatty acids, SIHUMI, multi-omics, dysbiosis, microbiome-targeted therapy, synthetic microbial communities